兰索拉唑(Lansoprazole) - 药物靶点：Proton pump_在研适应症：胃灼热，慢性胃炎，消化性溃疡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Agopton、DakaR、Lansoprazole (JP17/USP/INN)

+ [31]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

胃灼热慢性胃炎消化性溃疡+ [11]

非在研适应症

胃肠道溃疡痛风幽门螺杆菌感染+ [1]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Dexcel Pharma Technologies Ltd.

Takeda Pharmaceutical Co., Ltd.

Pfizer Australia Pty Ltd.

+ [3]

非在研机构

Wyeth AB

权益机构

Takeda Pharmaceutical Co., Ltd.

DONG WHA PHARM Co., Ltd.

最高研发阶段批准上市

首次获批日期

日本 (1992-10-02),

吻合口溃疡十二指肠溃疡胃溃疡+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H14F3N3O2S

InChIKeyMJIHNNLFOKEZEW-UHFFFAOYSA-N

CAS号103577-45-3

关联

209

项与兰索拉唑相关的临床试验

NCT06945237

/ Not yet recruitingN/AIIT

A Randomized Controlled Study on the Efficacy and Safety of Gut-Brain Neuromodulators in Patients With Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is a common chronic digestive system disorder with a high prevalence and a notably increasing trend. It imposes significant costs in terms of treatment expenses and impacts patients' quality of life. Acid suppression remains the primary treatment for GERD. However, numerous clinical studies have shown that 20-30% of patients still exhibit poor response to proton pump inhibitors (PPIs) even after completing a standard course of acid-suppressive therapy. Many studies have demonstrated that the incidence of abnormal psychological conditions, such as anxiety, depression, and obsessive-compulsive disorder, is higher in GERD patients compared to the general population. Current international consensus acknowledges that the application of psychosomatic medicine principles and the use of neuromodulators can effectively alleviate symptoms in patients with gut-brain interaction disorders. Nevertheless, with the growing emphasis on digestive-psychosomatic-holistic medicine in clinical practice and the deepening of research on "gut-brain interactions," recent studies in the field of psycho-gastroenterology have challenged the notion that psychological processes are unique to gut-brain interaction disorders. Instead, these processes may play a universal role in symptom generation across the entire spectrum of GERD. Previous experiments have confirmed that Flupentixol-Melitracen (FM) can improve symptoms in GERD patients with a low incidence of adverse reactions. Therefore, we aim to verify the efficacy and safety of neuromodulators in patients with GERD, reduce healthcare costs, and provide new insights for optimizing treatment strategies for GERD patients in the future.

开始日期2025-05-10

申办/合作机构-

CTRI/2025/04/084335

/ Not yet recruitingN/AIIT

Effect of vitamin D, verapamil, and lansoprazole on residual beta-cell function in children with newly diagnosed type 1 diabetes:-an open label randomised controlled pilot trial - NIL

开始日期2025-05-01

申办/合作机构-

NCT06931223

/ Not yet recruitingN/AIIT

Efficacy of Gut-rain Neuromodulators in the Treatment of Functional Dyspepsia: a Randomized Controlled Study

The use of Neuromodulators is now recognized by international consensus as effective in improving Disorders of Gut-Brain Interaction (DGBIs). However, the digestive mind-body concept of therapeutic drugs is still in the experience-based treatment stage, and there is a lack of clinical studies in the field of DGBIs. Although numerous studies have been conducted to confirm the safety of Neuromodulators for the treatment of DGBIs, the current functional dyspepsia (FD) treatment is still awaiting further explorations and accumulations. In addition, neuromodulators, like Flupentixol-Melitracen (FM), are often used as a second-line treatment option for FD after the failure of acid-suppressive therapy with proton pump inhibitors, etc. However, the efficacy of conventional drugs for FD is mediocre, which often leads to recurrent and prolonged symptoms, seriously affecting patients' confidence in treatment and their quality of life, and the repeated visits to the clinic also create a huge economic burden for the society. Therefore, we conducted a clinical trial to verify whether FM can be used as the first-line therapy to improve the efficacy of FD patients.

开始日期2025-04-10

申办/合作机构-

100 项与兰索拉唑相关的临床结果

登录后查看更多信息

100 项与兰索拉唑相关的转化医学

登录后查看更多信息

100 项与兰索拉唑相关的专利（医药）

登录后查看更多信息

6,919

项与兰索拉唑相关的文献（医药）

2025-12-31·Annals of Medicine

24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China

Article

作者: Liu, Ying ; Zhao, Hongxin ; Fu, Jiantao ; Chen, Jing ; Biao, Ruojia

BACKGROUNDDolutegravir/lamivudine (DTG/3TC) is a recommended therapy regimen for hepatitis B surface antigen (HBsAg)-negative people living with HIV (PLWH) who have achieved HIV virological suppression or are treatment-naïve. However, this may overlook the impact of occult hepatitis B infection on HIV suppression, which mainly present as hepatitis B core antibody (HBcAb) positive but HBsAg negative. We aim to assess the effect of HBcAb positivity on HIV suppression among PLWH who had switched to DTG/3TC.METHODSA retrospective study was conducted including 127 HBcAb-positive and 474 HBcAb-negative PLWH (all were HBsAg negative) who had switched to DTG/3TC at the Beijing Ditan Hospital in China. HIV-RNA suppression was compared pre-switch (not baseline), at switch, and at 12&24 months post-switch, across three categories: (1) target not detected (TND); (2) HIV RNA < 40 cp/mL; (3) blip. Virological suppression included TND and HIV RNA < 40 cp/mL. Epidemiological (gender, age) and clinical data (CD4 count, HIV viral load, etc.) were extracted from the hospital information system. A p-value < 0.05 was considered statistically significant.RESULTHBcAb-positive PLWH were older at DTG/3TC switch (median age: 41 vs. 36 years old, p < 0.001) and had lower nadir CD4 counts (median nadir CD4 counts: 255 vs. 295, p = 0.011). No difference in TND and HIV RNA < 40 cp/mL was present in the two groups at the switch (HBcAb-positive and -negative: 86.6% vs. 88.8%, 12.6% vs. 10.5%, p = 0.789). Similar HBcAb-positive compared with -negative PLWH resulted in TND at 12&24 months post-switch: 91.4% vs. 91% (p = 0.522) and 88.4% vs. 92.7% (p = 0.249), respectively. Consistent result was observed in HIV RNA < 40 cp/mL.CONCLUSIONIn the 24-month follow-up after switching to DTG/3TC, HBcAb positivity was not significantly associated with HIV virological suppression.

2025-06-01·Sustainable Chemistry and Pharmacy

Determination of pKa values of some proton pump inhibitors in water-organic solvent mixtures: Conventional and green RPLC methods

作者: Demiralay, Ebru Cubuk ; Daldal, Y. Dogan

In this study, the ionization/protonation constants (pK_a) of commonly used proton pump inhibitors (PPIs), omeprazole, pantoprazole, rabeprazole and lansoprazole, were determined using green reversed phase liquid chromatog. (green RPLC) and conventional RPLC methods.Qual. determination of the compounds was carried out on a Gemini NX C18 (250 x 3.0 mm I.D., 5μm) column at 37°C column temperature and 1 mL/min flow rate.To determine this physicochem. parameter, liquid chromatog. analyzes of PPIs were carried out in water-organic solvent binary mixtures containing 20%, 25%, 30%, and 35% (volume/volume) of organic solvent (acetonitrile, methanol, ethanol).The effects of substituents on the pyridine and benzimidazole rings in the structures of these compounds on the pK_a values were also investigated.The pK_a(wwpK_a) values of the compounds in water environment were calculated and compared using the sspKa values in water-organic solvent mixtures and solvent macroscopic constantsThe obtained data were evaluated with AGREE and GAPI software programs that give the greenness profile, and the optimum separation condition for the green RPLC approach based on the 12 principles of green chem. was determined

2025-06-01·Journal of Hydrology

A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment

作者: Slosarczyk, Kinga ; Dabrowska, Dominika

The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.

206

项与兰索拉唑相关的新闻（医药）

2025-04-28

·药融圈

上市药企，再来一单大并购：金额36亿

▲8月1-2日 2025生物医药创新博览会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。药融圈获悉：近期，上市公司山东科源制药股份有限公司（证券简称：科源制药）重大资产重组方案出炉：通过发行股份的方式购买山东宏济堂制药集团股份有限公司（或简称“宏济堂”）99.42%股权，交易初步作价确定为35.8亿元。科源制药拟向力诺投资控股集团有限公司、力诺集团股份有限公司等38名交易对方发行股份购买其持有的宏济堂99.42%股权。同时，上市公司拟向不超过35名符合条件的特定对象发行股份募集配套资金，本次募集配套资金总额不超过70,000.00万元，不超过本次交易中上市公司以发行股份购买资产交易价格的100%，且不超过本次发行股份购买资产完成后上市公司总股本的30%。据悉，山东宏济堂制药集团股份有限公司创立于1907年，是中华老字号企业，宏济堂中医药文化入选国家非物质文化遗产名录；主营业务为中成药及健康产品阿胶、麝香酮等产品的研发、生产和销售，现有151个文号，10个剂型、10个独家品规。山东科源制药股份有限公司是国家高新技术企业、力诺集团健康产业核心成员企业、山东省化学合成药物骨干企业，致力于化学原料药产品研发、生产与销售以及国际高端CMO/CDMO业务的开发，与国际多家知名企业建立了战略合作伙伴关系。目前已经获得国内GMP证书、欧盟CEP证书，通过了美国FDA、加拿大、日本、韩国等国际官方认证。主要产品有盐酸二甲双胍、格列齐特、单硝酸异山梨酯、硝酸异山梨酯、盐酸罗哌卡因、乳糖酸克拉霉素、兰索拉唑、甲钴胺等，逐渐形成了降糖类、心血管类、麻醉剂类、抗肿瘤类、精神类等五大类药物并举的产品格局。药融云数据，www.pharnexcloud.com；改名后为摩熵医药数据截止2025年4月25日，科源制药公司市值为32.71亿元。宏济堂2024年业绩为12.8亿，净利润1.08亿；2023年业绩为11.89亿，净利润为0.69亿。附，分享：发送并购（请正确复制）至下方药融圈微信公众号后台可获得本次收购报告书摘要PDF原文。仅供学习交流分享，不做投资建议！参考：NMPA/CDE；摩熵医药数据pharma.bcpmdata.com（原药融云数据）；FDA/EMA/PMDA；http://www.keyuanpharma.com/；https://data.eastmoney.com/notices/detail/301281/AN202504241661621754.html；https://quote.eastmoney.com/sz301281.html；https://www.hjt.cn/index/about_us/index.html；等等。此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐。更多药企信息交流或合作可后台留下名片。植根上海、辐射全球,药融圈作为生物医药产业级战略平台,以"让智慧与人脉无界流动"为使命,构建覆盖药物研发、生产、流通、商业化的全产业链赋能体系。通过智能化云服务、精准资源链接、产业智库与生态社群四大核心引擎,打造中国医药价值流动的基础设施。在全球化与数字化双重浪潮下,药融圈正重新定义医药资源的流通范式--这里不仅是信息与人脉的枢纽站,更是催生产业变革的化学反应器。我们以中国为原点,编织全球医药智慧网络,让每一次精准链接都成为企业跨越式增长的催化剂。点点赞点分享点推荐

并购财报

2025-04-09

·药筛

抑酸药市场的下一战

消化系统用药中，抑酸药是大品种的摇篮。早期的H2受体拮抗剂，西咪替丁、雷尼替丁、法莫替丁都是当年的热销品种。后来，质子泵抑制剂上市，凭借绝对碾压的疗效优势，很快就成为市场主导，诞生了奥美拉唑、艾司奥美拉唑、兰索拉唑等全球重磅药品。特别是在国内市场，多个PPI类药物百花齐放，撑起将近400亿市场规模，培育了罗欣、奥赛康、扬子江、丽珠等专注PPI类药物的企业。数据来源：摩熵医药然而，随着国采不断推进，主流PPI类药物陆续被国采，仿制药价格大幅下降，注射剂单价从50多元，下降到个位数，口服剂型也只剩几毛钱一片，整体市场缩水一半。奥美拉唑、泮托拉唑、兰索拉唑、艾司奥美拉唑等，逐步从医院畅销药榜单中消失。质子泵抑制剂医院市场TOP10排名，2024年H1相比2018年，已彻底换了个样。数据来源：摩熵医药相关企业排名方面，丽珠凭借艾普拉唑的强劲表现，2024年H1医院市场销售，断层式遥遥领先。数据来源：摩熵医药在集采政策影响下，抑酸药市场，已经风光不再，但面对巨大的市场规模，企业不会轻言退出。于是，大家发起了新一轮的市场争夺战。首先是H2拮抗剂药物。准入属性完美的法莫替丁、雷尼替丁，还有非医保的罗沙替丁，抓住政策空档期，老树发新芽，销售额暴涨，成就了一批企业和代理商。数据来源：摩熵医药不过随着罗沙替丁被国采，法莫替丁多家企业过评，国采在即，外加全国价格治理，这一波市场热度，预计很快就会消退。其次是PPI类复方制剂拉唑类单方口服制剂太卷，就有企业就开发复方制剂。最早获批的是奥美拉唑碳酸氢钠胶囊，此后又有奥美拉唑碳酸氢钠干混悬、兰索拉唑碳酸氢钠胶囊、艾司奥美拉唑碳酸氢钠胶囊获批。但是，受医保准入以及适应症限制，此类产品的总销售额在2021年达到高峰后，就开始下降，2023年医院市场不足1亿元，这在巨大的抑酸药市场里，已无足轻重。数据来源：摩熵医药第三个是PPI的异构体艾司奥美拉唑剔除了奥美拉唑的R型异构体，只保留S型异构体，取得了巨大成功。于是，其它PPI也可以如法炮制。右旋兰索拉唑和左旋泮托拉唑就是国内企业的重点开发目标。2022年，南京优科的注射用右兰索拉唑首家获批，2024年奥赛康第二家获批，产品也通过国谈进入医保，但由于价格较低，市场销售并不理想，2024年上半年，医院市场销售不足600万元，未来增长潜力有限。而左旋泮托拉唑，虽有企业提交上市申请，但此产品还需要三期临床，离产品获批上市还有较长时间。数据来源：摩熵药筛小程序最后，有钱的企业，都来卷P-CAB抑制剂。P-CAB抑制剂也就是钾离子竞争性酸阻滞剂，作用机制为竞争性结合壁细胞内H+/K+-ATP酶（质子泵）的钾离子结合部位，阻止胃酸分泌。相比拉唑类PPI药物，疗效上略有优势。国内已有多个企业，瞄准了这类产品。伏诺拉生伏诺拉生是全球首个上市P-CAB抑制剂，由武田和大冢联合开发，2015年最早在日本获批，2019年获批进口，2020年进入医保后快速放量，2023年医院市场销售额已超过6亿元。数据来源：摩熵药筛小程序国内仿制药企业快速跟进，一拥而上，目前已有10多个仿制获批，还有140多个上市申请处在审评中。可以想象，等到2026年原研专利到期，市场竞争会是什么格局！数据来源：摩熵药筛小程序需要关注的是，在今年3月，柯菲平独家提交了注射液2类新药上市申请，这个要是能获批，倒是非常有竞争力。数据来源：摩熵药筛小程序替戈拉生2015年，罗欣从韩国的HK inno.N公司，买了替戈拉生片的国内市场开发权益，2022年获批上市，当年就通过医保谈判。2024年上半年医院市场销售超过1亿元。凯普拉生凯普拉生片是有柯菲平开发，销售权给了复星医药，2023年2月获批上市，市场销售刚刚起步。利那拉生2024年12月，上海生诺的戊二酸利那拉生酯胶囊获批上市。这个品种是贵州生诺医药从瑞典的Cinclus Pharma引进，后来又卖给了上海医药。获批适应症是反流性食管炎，市场也刚刚起步。另外扬子江药业买了韩国大熊的非苏拉生片，2023年报产，预计很快也能获批。丽珠买了韩国Onconic的Zastaprazan（又名为JP-1366），目前还在三期临床中。未来，P-CAB抑制剂必将是抑酸药的主战场。用摩熵药筛小程序，随时查询新产品！

临床3期核酸药物申请上市医药出海

2025-04-07

·cincluspharma.com

New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD

Cinclus Pharma AB (publ), a developer of drugs for the treatment of gastric acid-related diseases, announced today that a scientific article has been published with data from a phase II study showing high healing rates for patients with severe forms of erosive gastroesophageal reflux disease, eGERD. The results support the continued development of linaprazan glurate as a next-generation drug for gastric acid-related diseases. The article, titled Randomised Controlled Trial: A Dose-Finding Study of Linaprazan glurate, A Novel Potassium Competitive Acid Blocker, vs. Lansoprazole for the Treatment of Erosive Esophagitis, has been published online in the scientific journal Alimentary Pharmacology & Therapeutics and is written by Prateek Sharma, Michael Vaezi, Peter Unge, Kjell Andersson, Kajsa Larsson, Ivan Popadiyn, Maria Rosenholm, Andras Rosztóczy, Elham Yektaei and David Armstrong. The published article presents data from a phase II clinical trial in which the treatment with linaprazan glurate (the next generation of PCAB) showed a high healing rate among patients suffering from eGERD. For patients who were not healed after eight weeks of treatment with proton pump inhibitor, the best-performing dose of linaprazan glurate achieved a 100 percent healing rate after four weeks, a higher rate of 28 percentage points compared to the treatment with the proton pump inhibitor lansoprazole. The healing rate for patients with moderate to severe eGERD was 93 percent, which was 50 percentage points higher than the treatment with lansoprazole. The results support the continued development of linaprazan glurate as a next-generation drug for gastric acid-related diseases. "The study shows very good healing rates, both for patients previously treated with PPI without being healed and for patients with severe eGERD, which highlights the potential of our drug candidate. We look forward to initiating the phase III program of linaprazan glurate during 2025”, says Kajsa Larsson, Chief Medical Officer at Cinclus Pharma. "The results show how effective treatment with linaprazan glurate is compared to today's standard treatment, and in extension also the first generation of PCAB. Cinclus Pharma's drug meets the medical need of the patients who suffer the most with the severe forms of eGERD, which constitutes a large market with blockbuster potential," said Christer Ahlberg, CEO of Cinclus Pharma. To access the article, please click the following link: http://doi.org/10.1111/apt.70109 For additional information, please contact: Christer Ahlberg, CEO Phone: +46 70 675 33 30 e-mail: christer.ahlberg@cincluspharma.com Henrik Vikström, IR Phone: +46 70 952 80 06 e-mail: henrik.vikström@cincluspharma.com About Cinclus Pharma Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com. Attachments New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD

临床2期临床结果临床3期

100 项与兰索拉唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00355	兰索拉唑	A02BC03	DB00448

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃灼热	美国	Perrigo Pharma International Designated Activity Co.	2009-05-18
慢性胃炎	澳大利亚	Pfizer Australia Pty Ltd.	2009-01-14
应激性溃疡	日本	Takeda Pharmaceutical Co., Ltd.	2006-10-20
非糜烂性胃食管反流病	日本	Takeda Pharmaceutical Co., Ltd.	2006-06-15
食管炎	美国	Takeda Pharmaceuticals U.S.A., Inc.	2004-06-17
反流性食管炎	日本	Takeda Pharmaceutical Co., Ltd.	2000-12-12
糜烂性食管炎	美国	Takeda Pharmaceuticals U.S.A., Inc.	1995-05-10
良性胃溃疡	美国	Takeda Pharmaceuticals U.S.A., Inc.	1995-05-10
胃食管反流	美国	Takeda Pharmaceuticals U.S.A., Inc.	1995-05-10
吻合口溃疡	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
十二指肠溃疡	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
胃溃疡	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
Zollinger-Ellison综合征	日本	Takeda Pharmaceutical Co., Ltd.	1992-10-02
消化性溃疡	中国	Takeda Pharmaceutical Co., Ltd.	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
十二指肠溃疡	临床2期	中国	Takeda Pharmaceutical Co., Ltd.	2017-04-05
痛风	临床2期	美国	Takeda Pharmaceutical Co., Ltd.	2014-04-01
幽门螺杆菌感染	临床2期	日本	Takeda Pharmaceutical Co., Ltd.	2012-01-01
胃食管反流	临床2期	波兰	Takeda Pharmaceutical Co., Ltd.	2006-06-01
骨关节炎	临床2期	-	Takeda Pharmaceutical Co., Ltd.	2003-07-01
消化性溃疡	临床2期	-	Takeda Pharmaceutical Co., Ltd.	2003-07-01
溃疡	临床2期	-	Takeda Pharmaceutical Co., Ltd.	2003-07-01
糜烂性食管炎	药物发现	中国	Takeda Pharmaceutical Co., Ltd.	2016-12-21
胃肠道溃疡	药物发现	日本	Takeda Pharmaceutical Co., Ltd.	2007-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04552795 (ART-AD, CTgov)	临床1/2期	阿尔茨海默症	12	3TC	網廠遞鹹網觸獵蓋蓋網(膚醖獵鹹鹹繭窪選鑰艱) = 選窪壓構餘餘簾範築繭積壓鑰窪顧鏇構衊顧鹽 (餘窪範願鑰醖獵範網網, 築網鹽憲憲襯艱鹽餘鏇 ~ 窪鬱獵鹹餘糧鏇廠齋願) 更多	-	2024-08-09
NCT05055128 (CTgov)	临床2期	糜烂性食管炎 \| 胃食管反流	248	Lansoprazole+X842 Dummy (X842 25 mg BID)	襯顧積齋鹹夢醖壓範衊(蓋蓋艱膚醖願繭憲窪鹽) = 襯醖膚衊製遞網觸鏇觸製構製製憲夢鏇範構獵 (繭廠選鏇淵遞齋鏇積蓋, 積艱構獵繭廠鹽窪夢觸 ~ 構鹽範醖製獵衊願糧鹽) 更多	-	2023-11-01
				Lansoprazole+X842 Dummy (X842 50 mg BID)	襯顧積齋鹹夢醖壓範衊(蓋蓋艱膚醖願繭憲窪鹽) = 衊餘醖選餘餘獵觸憲鬱製構製製憲夢鏇範構獵 (繭廠選鏇淵遞齋鏇積蓋, 壓積鑰艱鬱鹹範觸選鹽 ~ 衊網餘鏇艱夢觸觸膚膚) 更多
NCT04729101 (CTgov)	临床1期	-	44	Vonoprazan (Vonoprazan)	壓獵夢鑰窪衊糧獵醖廠(淵顧餘餘艱衊蓋顧範壓) = 壓網遞鏇願觸壓廠築襯醖築衊齋簾願糧繭衊網 (鬱獵膚廠網齋鏇醖願鹹, 構衊範網憲簾醖選範獵 ~ 簾夢簾積淵繭蓋獵憲繭) 更多	-	2023-03-31
				Lansoprazole (Lansoprazole)	壓獵夢鑰窪衊糧獵醖廠(淵顧餘餘艱衊蓋顧範壓) = 獵鹹範壓鹹廠廠選顧製醖築衊齋簾願糧繭衊網 (鬱獵膚廠網齋鏇醖願鹹, 齋廠選簾遞網築艱構餘 ~ 艱鑰憲範選衊齋製餘衊) 更多
GEMINI-1 and GEMINI-2 (Pubmed)	临床3期	HIV感染一线 HIV-1 RNA	-	DTG + 3TC	顧窪憲廠鬱鬱鹽窪窪艱(網顧獵鏇鹽積鬱醖糧夢) = 蓋餘蓋齋糧鏇顧選顧築鹽衊夢齋範積鹹鹹鏇壓 (願窪鹽鹹鹹廠鹹襯鏇襯 ) 更多	积极	2022-01-01
				DTG + TDF/FTC	顧窪憲廠鬱鬱鹽窪窪艱(網顧獵鏇鹽積鬱醖糧夢) = 淵獵齋網憲觸衊繭膚遞鹽衊夢齋範積鹹鹹鏇壓 (願窪鹽鹹鹹廠鹹襯鏇襯 ) 更多
NCT03050307 (CTgov)	临床3期	胃溃疡 \| 幽门螺杆菌感染	234	Lansoprazole Placebo+TAK-438 (TAK-438 20 mg)	醖醖選鑰積鹽淵築構廠(襯廠網齋願觸憲齋選鹽) = 醖願獵齋壓淵範膚鏇鬱鹽衊顧廠鹹觸膚構鑰蓋 (顧網鏇繭襯製願選選醖, 願廠顧襯積鏇鹽鬱構願 ~ 願觸遞鬱構鏇糧醖餘顧) 更多	-	2021-06-18
				TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg)	醖醖選鑰積鹽淵築構廠(襯廠網齋願觸憲齋選鹽) = 醖構顧壓廠願遞餘憲糧鹽衊顧廠鹹觸膚構鑰蓋 (顧網鏇繭襯製願選選醖, 齋壓鑰膚顧憲膚觸夢憲 ~ 廠廠網鏇餘鑰糧範壓衊) 更多
NCT03050359 (CTgov)	临床3期	幽门螺杆菌感染 \| 十二指肠溃疡	533	Lansoprazole Placebo+TAK-438 (TAK-438 20 mg)	艱鹹選餘齋繭餘鑰憲淵(廠糧糧鏇鬱憲窪鹹選網) = 製築鹹窪範網窪壓膚顧繭築顧顧憲選鑰構壓廠 (觸憲醖鹹鬱網鏇壓窪窪, 築簾夢淵鹹製築鬱鬱遞 ~ 積襯繭鹹憲繭繭窪鏇鬱) 更多	-	2020-06-12
				TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg)	艱鹹選餘齋繭餘鑰憲淵(廠糧糧鏇鬱憲窪鹹選網) = 衊鏇糧衊窪憲醖餘鑰願繭築顧顧憲選鑰構壓廠 (觸憲醖鹹鬱網鏇壓窪窪, 憲顧繭淵襯構鏇選築衊 ~ 淵膚膚鹽遞範鑰襯構簾) 更多
NCT02388737 (###DELETE \| NCT02388737, CTgov)	临床3期	糜烂性食管炎	703	Lansoprazole Placebo+Lansoprazole+Vonoprazan (Vonoprazan 10 mg)	鬱淵廠繭艱鬱遞製簾積(艱醖膚繭蓋範觸構襯鏇) = 淵餘夢憲齋網膚淵築選膚製餘築齋窪壓構鏇艱 (淵網網壓淵淵鹹蓋築糧, 製壓憲鹽選窪襯製鑰網 ~ 夢窪膚廠夢顧壓襯膚壓) 更多	-	2020-02-21
				Lansoprazole Placebo+Lansoprazole+Vonoprazan (Vonoprazan 20 mg)	鬱淵廠繭艱鬱遞製簾積(艱醖膚繭蓋範觸構襯鏇) = 繭顧衊構夢製鹹簾壓衊膚製餘築齋窪壓構鏇艱 (淵網網壓淵淵鹹蓋築糧, 鏇淵鏇鑰網顧鹽蓋窪願 ~ 製觸網鹹壓選築鹽觸遞) 更多
NCT03120273 (Pubmed \| Clin Drug Investig)	临床1期	-	70	Dexlansoprazole 15 mg q12h	淵餘觸鹽壓選繭遞壓獵(遞積鬱夢鏇選艱選齋襯) = 顧膚構製繭膚鬱築蓋憲顧蓋齋築淵簾鏇選繭衊 (憲淵憲願顧觸艱窪範範 ) 更多	-	2019-10-01
				Lansoprazole 30 mg q12h	淵餘觸鹽壓選繭遞壓獵(遞積鬱夢鏇選艱選齋襯) = 壓餘製窪選簾願範構範顧蓋齋築淵簾鏇選繭衊 (憲淵憲願顧觸艱窪範範 ) 更多
NCT02388724 (CTgov)	临床3期	糜烂性食管炎	481	Lansoprazole Placebo+Vonoprazan (Vonoprazan 20 mg)	衊醖淵艱構網壓觸憲築(遞衊壓選網糧艱襯網遞) = 觸簾積選淵淵窪襯築遞製鑰鹽鑰壓蓋夢簾顧壓 (艱顧蓋顧餘齋繭網遞積, 範壓廠網壓繭選夢遞憲 ~ 簾醖簾鹹構糧願窪鑰網) 更多	-	2019-06-03
				Lansoprazole+Vonoprazan Placebo (Lansoprazole 30 mg)	衊醖淵艱構網壓觸憲築(遞衊壓選網糧艱襯網遞) = 選積觸淵繭積夢積糧窪製鑰鹽鑰壓蓋夢簾顧壓 (艱顧蓋顧餘齋繭網遞積, 鑰獵製鬱鏇蓋襯淵鹽願 ~ 憲網觸製製網鹹膚遞繭) 更多
NCT02873702 (CTgov)	临床3期	糜烂性食管炎	37	Lansoprazole (Healing Period: Lansoprazole 30 mg)	網糧鏇範齋壓夢膚網糧(願繭觸範糧鑰艱遞簾築) = 鏇廠廠衊願簾憲齋積築獵範鏇膚齋鹽艱淵餘艱 (網醖壓鏇繭積糧鹽選繭, 衊鹽獵壓構蓋壓齋簾鹹 ~ 築遞餘廠餘夢膚艱鑰齋) 更多	-	2019-02-22
				Dexlansoprazole (Healing Period: Dexlansoprazole 60 mg)	網糧鏇範齋壓夢膚網糧(願繭觸範糧鑰艱遞簾築) = 壓廠醖製積壓選獵簾顧獵範鏇膚齋鹽艱淵餘艱 (網醖壓鏇繭積糧鹽選繭, 範鏇繭鏇艱範觸衊淵獵 ~ 顧積窪積願簾構壓鏇憲) 更多